Αποτελέσματα Αναζήτησης
Vaccination is the primary method for prevention of both CAV-2 and CAV-1 disease. The most widely used and effective vaccine for both types of canine adenovirus is an MLV vaccine containing CAV-2. The MLV CAV-2 vaccine provides cross-protection against CAV-1 and therefore also prevents infectious canine hepatitis.
17 Αυγ 2022 · Key Vaccination: Bordetella, Canine Parainfluenza, and Canine Influenza. Canine adenovirus type 2 (CAV-2) is considered a core vaccine, primarily because it is necessary for the prevention of canine adenovirus type 1 (CAV-1) (against which it cross-protects), 18 the cause of infectious canine hepatitis, historically recognized as a severe and ...
Disease Overview. Canine adenovirus type 2 (CAV-2) is related to the hepatitis virus, canine adenovirus type 1 (CAV-1). CAV-2 is used in vaccines to provide protection against canine infectious hepatitis. CAV-2 is also one of the causes of infectious tracheobronchitis, also known as canine cough. 30.
21 Οκτ 2020 · The study determined anti-CAV antibodies within 28 days of re-vaccination and factors associated with the absence of antibodies and vaccination response. Methods: Ninety-seven healthy adult dogs (last vaccination ≥12 months) were re-vaccinated with a modified live CAV-2 vaccine.
One dose of a MLV canine core vaccine (CDV, CPV‐2 CAV‐2) or MLV FPV vaccine should provide long term immunity when given to animals at or after 16 weeks of age. Every puppy and kitten 16 weeks of age or older should receive at least one dose of MLV core vaccines.
Although the disease results from infection by CAV-1, administration of live, attenuated CAV-2 vaccine results in adequate protection. Supportive care is aimed at maintaining fluid balance, addressing hepatic dysfunction, managing the coagulopathic state, and treating secondary bacterial infections.
27 Σεπ 2010 · A very effective vaccine based on an avirulent CAV-2 vector is used worldwide for the routine vaccination against both canine infectious hepatitis (CAV-1) and canine infectious laryngotracheitis (CAV-2), with an excellent safety record.
